{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:01:33Z","timestamp":1789678893033,"version":"4.0.1"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.blre.2023.101103","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:11:27Z","timestamp":1686550287000},"page":"101103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme"],"prefix":"10.1016","volume":"61","author":[{"given":"Myrthe J.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.A.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke A.E.","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard J.","family":"van Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.blre.2023.101103_bb0005","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood-2005-04-1622","article-title":"The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis","volume":"106","author":"Van Wijk","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101103_bb0010","series-title":"The red blood cell","author":"Surgenor","year":"1974"},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/yea.986","article-title":"A history of research on yeasts 5: the fermentation pathway","volume":"20","author":"Barnett","year":"2003","journal-title":"Yeast"},{"key":"10.1016\/j.blre.2023.101103_bb0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1039\/ca8783400019","volume":"34","year":"1878","journal-title":"J Chem Soc Abstr"},{"key":"10.1016\/j.blre.2023.101103_bb0025","article-title":"Of fixed acids","volume":"65","author":"Thomson","year":"1838","journal-title":"Chem Org Bodies Veg"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jlac.18350130109","article-title":"Ueber eine neue, durch Destillation von Wein-und Traubens\u00e4ure erhaltene S\u00e4ure","volume":"13","author":"Berzelius","year":"1835","journal-title":"Ann Pharm"},{"key":"10.1016\/j.blre.2023.101103_bb0035","doi-asserted-by":"crossref","first-page":"100380","DOI":"10.1016\/j.coisb.2021.100380","article-title":"Glycolysis: how a 300yr long research journey that started with the desire to improve alcoholic beverages kept revolutionizing biochemistry","volume":"28","author":"Gr\u00fcning","year":"2021","journal-title":"Curr Opin Syst Biol"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0021-9258(20)76366-0","article-title":"Otto Fritz Meyerhof and the elucidation of the glycolytic pathway","volume":"280","author":"Kresge","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0045","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/cells10040762","article-title":"The metabolic fates of pyruvate in Normal and neoplastic cells","volume":"10","author":"Prochownik","year":"2021","journal-title":"Cells."},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1022498714522","article-title":"Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield","volume":"29","author":"Brand","year":"1997","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.blre.2023.101103_bb0055","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1039\/tf9373300956","article-title":"A relation between the permeability of the red cell and its metabolism","author":"Wilbrandt","year":"1937","journal-title":"Prop Funct Membr Nat Artif Trans Faraday Soc"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01591-w","article-title":"\u2018Gardos Channelopathy\u2019: a variant of hereditary Stomatocytosis with complex molecular regulation","volume":"7","author":"Fermo","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.blre.2023.101103_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25419","article-title":"Erythrocyte ATP, a possible therapeutic approach for sickle cell disease","volume":"94","author":"Hoffman","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0070","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V69.4.999.999","article-title":"Impaired nicotinamide adenine dinucleotide synthesis in pyruvate kinase- deficient human erythrocytes: a mechanism for decreased total NAD content and a possible secondary cause of hemolysis","volume":"69","author":"Zerez","year":"1987","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101103_bb0075","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/cells8080890","article-title":"Regulation of glucose metabolism by NAD+ and ADP-ribosylation","volume":"8","author":"Hopp","year":"2019","journal-title":"Cells."},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01901136","article-title":"ATP-dependent Ca++-extrusion from human red cells","volume":"22","author":"Schatzmann","year":"1966","journal-title":"Experientia."},{"issue":"25","key":"10.1016\/j.blre.2023.101103_bb0085","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2017-04-590810","article-title":"Disorders of erythrocyte hydration","volume":"130","author":"Gallagher","year":"2017","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2023.101103_bb0090","doi-asserted-by":"crossref","first-page":"18145","DOI":"10.1074\/jbc.M001870200","article-title":"The allosteric regulation of pyruvate kinase","volume":"275","author":"Valentini","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2023.101103_bb0095","first-page":"355","article-title":"Energy metabolism and maintenance of erythrocytes","author":"Beutler","year":"2001","journal-title":"Williams Hematology"},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0100","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1021\/bi00834a046","article-title":"The oxygenation of hemoglobin in the presence of 2,3-diphosphoglycerate. Effect of temperature, pH, ionic strength, and hemoglobin concentration","volume":"8","author":"Benesch","year":"1969","journal-title":"Biochemistry."},{"issue":"November","key":"10.1016\/j.blre.2023.101103_bb0105","first-page":"1","article-title":"Generation and export of red blood cell ATP in health and disease","volume":"12","author":"McMahon","year":"2021","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oxfordjournals.jbchem.a128639","article-title":"Crystallization, characterization and metabolic regulation of two types of pyruvate kinase isolated from rat tissues*","volume":"62","author":"Tanaka","year":"1967","journal-title":"J Biochem"},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0079-6107(93)90001-Z","article-title":"Evolution of glycolysis","volume":"59","author":"Fothergill-Gilmore","year":"1993","journal-title":"Prog Biophys Mol Biol"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0120","first-page":"467","article-title":"Change of pyruvate kinase isozymes from M2- to L-type during development of the red cell","volume":"54","author":"Takegawa","year":"1983","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood.V64.3.607.607","article-title":"Changes in activities and isozyme patterns of glycolytic enzymes during erythroid differentiation in vitro","volume":"64","author":"Nijhof","year":"1984","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0009-8981(74)90301-5","article-title":"Further evidence of molecular alteration and aberration of erythrocyte pyruvate kinase","volume":"55","author":"Nakashima","year":"1974","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0135","first-page":"69","article-title":"The relationship of red cell enzymes to red cell life-span","volume":"14","author":"Beutler","year":"1988","journal-title":"Blood Cells"},{"issue":"13","key":"10.1016\/j.blre.2023.101103_bb0140","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1021\/bi00658a028","article-title":"Dual divalent cation requirement for activation of pyruvate kinase: essential roles of both enzyme- and nucleotide-bound metal ions","volume":"15","author":"Gupta","year":"1976","journal-title":"Biochemistry."},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0009-8981(77)90143-7","article-title":"Influence of the redox state of glutathione upon pyruvate kinase in the intact erythrocyte","volume":"80","author":"Sprengers","year":"1977","journal-title":"Clin Chim Acta"},{"issue":"6060","key":"10.1016\/j.blre.2023.101103_bb0150","first-page":"1278","article-title":"Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses","volume":"334","author":"Anastasiou","year":"2011","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/13543776.2018.1391218","article-title":"Pyruvate kinase activators as a therapy target: a patent review 2011-2017","volume":"28","author":"Adem","year":"2018","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"10.1016\/j.blre.2023.101103_bb0160","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.chembiol.2012.07.021","article-title":"Small molecule activation of PKM2 in cancer cells induces serine auxotrophy","volume":"19","author":"Kung","year":"2012","journal-title":"Chem Biol"},{"issue":"8","key":"10.1016\/j.blre.2023.101103_bb0165","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.tibs.2008.05.006","article-title":"New roles for pyruvate kinase M2: working out the Warburg effect","volume":"33","author":"Ferguson","year":"2008","journal-title":"Trends Biochem Sci"},{"issue":"3191","key":"10.1016\/j.blre.2023.101103_bb0170","first-page":"309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science (1979)"},{"issue":"7184","key":"10.1016\/j.blre.2023.101103_bb0175","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature."},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0180","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3892\/ol.2016.4168","article-title":"PKM2 and cancer: the function of PKM2 beyond glycolysis (review)","volume":"11","author":"Dong","year":"2016","journal-title":"Oncol Lett"},{"issue":"11","key":"10.1016\/j.blre.2023.101103_bb0185","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1016\/j.bmcl.2010.04.015","article-title":"Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"20","author":"Jiang","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.blre.2023.101103_bb0195","series-title":"ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model","author":"Jiang","year":"2010"},{"issue":"11","key":"10.1016\/j.blre.2023.101103_bb0200","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","article-title":"AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency","volume":"130","author":"Kung","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101103_bb0205","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211066070","article-title":"Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias","volume":"12","author":"Al-Samkari","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2023.101103_bb0210","first-page":"298","article-title":"Preclinical pharmacokinetic\/pharmacodynamic relationships for AG-348, an investigational small-molecule activator of pyruvate kinase","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0215","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.604","article-title":"Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers","volume":"8","author":"Yang","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0220","article-title":"Decreased activity and stability of pyruvate kinase in hereditary hemolytic anemia: a potential target for therapy by AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase","volume":"134","author":"Rab","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2019.238865","article-title":"AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes","volume":"106","author":"Rab","year":"2021","journal-title":"Haematologica."},{"issue":"21","key":"10.1016\/j.blre.2023.101103_bb0230","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood.2020008635","article-title":"Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy","volume":"137","author":"Rab","year":"2021","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101103_bb0235","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144206","article-title":"The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a \u03b2-thalassemia mouse model","volume":"131","author":"Matte","year":"2021","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.blre.2023.101103_bb0240","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/bloodadvances.2020003604","article-title":"FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice","volume":"5","author":"Shrestha","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101103_bb0245","first-page":"1","article-title":"Safety, pharmacokinetics, and pharmacodynamics of etavopivat (FT-4202), an allosteric activator of pyruvate kinase-R, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-human phase 1 trial","author":"Forsyth","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0250","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.121.000743","article-title":"Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease","volume":"380","author":"Schroeder","year":"2022","journal-title":"J Pharm Exp Therapeut"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0255","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2021-145374","article-title":"Pharmacodynamic effects of AG-946, a highly potent next-generation activator of pyruvate kinase, in ex vivo treatment of red blood cells from sickle cell disease patients","volume":"138","author":"Rab","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0260","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2021-148381","article-title":"Phase 1 single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AG-946 in healthy volunteers","volume":"138","author":"Iyer","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000441-194709000-00005","article-title":"A new type of hereditary hemolytic jaundice without spherocytosis","volume":"214","author":"Haden","year":"1947","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.blre.2023.101103_bb0270","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1182\/blood.V9.5.414.414","article-title":"Autohemolysis and other changes resulting from the incubation in vitro of red cells from patients with congenital hemolytic anemia","volume":"9","author":"Selwyn","year":"1954","journal-title":"Blood."},{"issue":"340","key":"10.1016\/j.blre.2023.101103_bb0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/pgmj.30.340.81","article-title":"Haemolytic anaemia","volume":"30","author":"Selwyn","year":"1954","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.blre.2023.101103_bb0280","first-page":"100","article-title":"A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital non-spherocytic hemolytic anemia","volume":"74","author":"Valentine","year":"1961","journal-title":"Trans Assoc Am Physicians"},{"issue":"9","key":"10.1016\/j.blre.2023.101103_bb0285","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2019.241141","article-title":"Molecular heterogeneity of pyruvate kinase deficiency","volume":"105","author":"Bianchi","year":"2020","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22042204","article-title":"The interplay between drivers of erythropoiesis and iron homeostasis in rare hereditary anemias: tipping the balance","volume":"22","author":"Grootendorst","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0295","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1038\/s41598-023-31571-2","article-title":"Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency","volume":"13","author":"Zaninoni","year":"2023","journal-title":"Sci Rep"},{"issue":"26","key":"10.1016\/j.blre.2023.101103_bb0300","doi-asserted-by":"crossref","first-page":"23807","DOI":"10.1074\/jbc.M202107200","article-title":"Structure and function of human erythrocyte pyruvate kinase: molecular basis of nonspherocytic hemolytic anemia","volume":"277","author":"Valentini","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM196801112780203","article-title":"Life-span and organ sequestration of the red cells in pyruvate kinase deficiency","volume":"278","author":"Nathan","year":"1968","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101103_bb0310","first-page":"503","article-title":"Erythrocyte disorders leading to potassium loss and cellular dehydration","volume":"30","author":"Glader","year":"1979","journal-title":"Prog Clin Biol Res"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0315","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.2830070302","article-title":"Quinine protects pyruvate-kinase deficient red cells from dehydration","volume":"7","author":"Koller","year":"1979","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101103_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2018.00656","article-title":"Squeezing for life - properties of red blood cell deformability","volume":"9","author":"Huisjes","year":"2018","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0325","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V69.4.999.999","article-title":"Impaired nicotinamide adenine dinucleotide synthesis in pyruvate kinase- deficient human erythrocytes: a mechanism for decreased total NAD content and a possible secondary cause of hemolysis","volume":"69","author":"Zerez","year":"1987","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0330","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.95.6.3077","article-title":"Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia","volume":"95","author":"Boas","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.blre.2023.101103_bb0335","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2008-07-161166","article-title":"Red cell membrane: past, present, and future","volume":"112","author":"Mohandas","year":"2008","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0340","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2014-12-512772","article-title":"Anatomy of the red cell membrane skeleton: unanswered questions","volume":"127","author":"Lux","year":"2016","journal-title":"Blood."},{"issue":"49","key":"10.1016\/j.blre.2023.101103_bb0345","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1073\/pnas.2210819119","article-title":"Fatigue of red blood cells under periodic squeezes in ECMO","volume":"119","author":"Pan","year":"2022","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0350","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM196801112780203","article-title":"Life-span and organ sequestration of the red cells in pyruvate kinase deficiency","volume":"278","author":"Nathan","year":"1968","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0355","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3324\/haematol.11469","article-title":"Pyruvate kinase deficiency","volume":"92","author":"Zanella","year":"2007","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0360","first-page":"819","article-title":"The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: a viewpoint","volume":"6","author":"Valentine","year":"1980","journal-title":"Blood Cells"},{"issue":"3893","key":"10.1016\/j.blre.2023.101103_bb0365","first-page":"601","article-title":"Oxygen-hemoglobulin dissociation curves: effect of inherited enzyme defects of the red cell","volume":"165","author":"Delivoria-Papadopoulos","year":"1969","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0370","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.10380","article-title":"Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency","volume":"74","author":"Aizawa","year":"2003","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101103_bb0375","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.exphem.2005.07.008","article-title":"Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity","volume":"33","author":"Aizawa","year":"2005","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101103_bb0380","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.exphem.2007.05.005","article-title":"Glycolytic inhibition by mutation of pyruvate kinase gene increases oxidative stress and causes apoptosis of a pyruvate kinase deficient cell line","volume":"35","author":"Aisaki","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2023.101103_bb0385","doi-asserted-by":"crossref","first-page":"609103","DOI":"10.3389\/fphys.2020.609103","article-title":"A proposed concept for defective mitophagy leading to late stage ineffective erythropoiesis in pyruvate kinase deficiency","volume":"11","author":"van Vuren","year":"2021","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0390","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1172\/JCI106539","article-title":"Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency","volume":"50","author":"Mentzer","year":"1971","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2005.05527.x","article-title":"Red cell pyruvate kinase deficiency: molecular and clinical aspects","volume":"130","author":"Zanella","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101103_bb0400","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.2019000945","article-title":"Management of pyruvate kinase deficiency in children and adults","volume":"136","author":"Grace","year":"2020","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0405","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.3324\/haematol.2017.177857","article-title":"Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency","volume":"103","author":"van Straaten","year":"2018","journal-title":"Haematologica."},{"issue":"7","key":"10.1016\/j.blre.2023.101103_bb0410","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2016.87","article-title":"Safe and efficient gene therapy for pyruvate kinase deficiency","volume":"24","author":"Garcia-Gomez","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2023.101103_bb0415","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.omtm.2021.05.001","article-title":"Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency","volume":"22","author":"Fa\u00f1anas-Baquero","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"10.1016\/j.blre.2023.101103_bb0420","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1902678","article-title":"Safety and efficacy of mitapivat in pyruvate kinase deficiency","volume":"381","author":"Grace","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0425","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2021-147156","article-title":"Bone mineral density remains stable in pyruvate kinase deficiency patients receiving long-term treatment with mitapivat","volume":"138","author":"Al-Samkari","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2023.101103_bb0430","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa2116634","article-title":"Mitapivat versus placebo for pyruvate kinase deficiency","volume":"386","author":"Al-Samkari","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2023.101103_bb0435","first-page":"1","article-title":"Mitapivat for patients with pyruvate kinase deficiency who are regularly transfused (ACTIVATE-T): an international, single-arm, phase 3 trial","volume":"3026","author":"Glenth\u00f8j","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0440","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood-2022-168954","article-title":"Long-term improvements in patient-reported outcomes in patients with pyruvate kinase deficiency treated with mitapivat","volume":"140","author":"Kuo","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0445","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood-2021-147317","article-title":"Mitapivat improves ineffective erythropoiesis and reduces iron overload in patients with pyruvate kinase deficiency","volume":"138","author":"Van Beers","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101103_bb0450","first-page":"3","article-title":"Sickle cell disease and thalassemia: disorders of globin production","author":"Vichinsky","year":"2008","journal-title":"Am Soc Hematol"},{"issue":"10351","key":"10.1016\/j.blre.2023.101103_bb0455","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(22)01337-X","article-title":"Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study","volume":"400","author":"Kuo","year":"2022","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.blre.2023.101103_bb0460","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.blre.2023.101103_bb0465","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101103_bb0470","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica."},{"issue":"20","key":"10.1016\/j.blre.2023.101103_bb0475","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMra1404415","article-title":"The \u03b1-Thalassemias","volume":"371","author":"Piel","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2023.101103_bb0480","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1182\/blood-2011-12-397729","article-title":"Integrated protein quality-control pathways regulate free \u03b1-globin in murine \u03b2-thalassemia","volume":"119","author":"Khandros","year":"2012","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0485","first-page":"359","article-title":"Anemia 2,3-DPG and tissue oxygenation in beta-thalassemia heterozygotes","volume":"24","author":"Tassiopoulos","year":"1982","journal-title":"Nouv Rev Fr Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0490","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V63.4.803.803","article-title":"Inappropriately low red cell 2,3-diphosphoglycerate and p50 in transfused beta-thalassemia","volume":"63","author":"Correra","year":"1984","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0495","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.V49.3.463.463","article-title":"Intraerythrocytic adaptation (2,3 DPG,P50) in thalassemia minor","volume":"49","author":"Pearson","year":"1977","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0500","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/clinchem\/23.4.761","article-title":"Increased erythrocyte 2,3-Diphosphoglycerate in homozygous beta-thalassemia","volume":"23","author":"Kalofoutis","year":"1977","journal-title":"Clin Chem"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0505","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2022-163493","article-title":"Mitapivat improves markers of erythropoietic activity in long-term study of adults with alpha- or beta-non-transfusion-dependent thalassemia","volume":"140","author":"Kuo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101103_bb0510","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.HS9.0000821540.81071.fa","article-title":"ENERGIZE and ENERGIZE-T: two phase 3, randomized, double-blind, placebo-controlled studies of mitapivat in adults with nontransfusion- dependent or transfusion-dependent alpha- or beta-thalassemia","volume":"6","author":"Kuo","year":"2022","journal-title":"Hemasphere."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0515","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2021-145752","article-title":"Trial in Progress: a phase 2, open-label study evaluating the safety and efficacy of the PKR activator etavopivat (FT-4202) in patients with thalassemia or sickle cell disease","volume":"138","author":"Lal","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101103_bb0520","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.1910.00050330050003","article-title":"Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia","volume":"VI","author":"Herrick","year":"1910","journal-title":"Arch Intern Med (Chic)"},{"key":"10.1016\/j.blre.2023.101103_bb0525","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N Engl J Med"},{"issue":"May","key":"10.1016\/j.blre.2023.101103_bb0530","first-page":"1","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas Cisneros","year":"2020","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0535","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2008.07473.x","article-title":"Ca2+-CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle erythrocytes","volume":"144","author":"Sabina","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0540","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2003.04781.x","article-title":"Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells","volume":"124","author":"Banerjee","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101103_bb0545","doi-asserted-by":"crossref","first-page":"102660","DOI":"10.1016\/j.bcmd.2022.102660","article-title":"Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model","volume":"95","author":"Quezado","year":"2022","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0550","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1172\/JCI106294","article-title":"Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia","volume":"49","author":"Charache","year":"1970","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.blre.2023.101103_bb0555","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V85.11.3289.bloodjournal85113289","article-title":"Antisickling effects of 2,3-diphosphoglycerate depletion","volume":"85","author":"Poillon","year":"1995","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2023.101103_bb0560","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.2022015403","article-title":"A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease","volume":"140","author":"Xu","year":"2022","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101103_bb0565","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.26554","article-title":"Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study","volume":"97","author":"van Dijk","year":"2022","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0570","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2021-147091","article-title":"Activation of pyruvate kinase-R with etavopivat (FT-4202) is well tolerated, improves anemia, and decreases intravascular hemolysis in patients with sickle cell disease treated for up to 12 weeks","volume":"138","author":"Brown","year":"2021","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101103_bb0575","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2019-121889","article-title":"Phase 1 single (SAD) and multiple ascending dose (MAD) studies of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of FT-4202, an allosteric activator of pyruvate kinase-R, in healthy and sickle cell disease subjects","volume":"134","author":"Kalfa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101103_bb0580","first-page":"515","article-title":"De la microcyth\u00e9mie","volume":"5","author":"Vanlair","year":"1871","journal-title":"Bull R Acad Med Belg"},{"issue":"10","key":"10.1016\/j.blre.2023.101103_bb0585","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archinte.1975.00330100042007","article-title":"Herediatary spherocytosis. A review","volume":"135","author":"Weed","year":"1975","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101103_bb0590","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2004.05052.x","article-title":"Guidelines for the diagnosis and management of hereditary spherocytosis","volume":"126","author":"Bolton-Maggs","year":"2004","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0595","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.mcna.2016.09.008","article-title":"Congenital hemolytic anemia","volume":"101","author":"Haley","year":"2017","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.blre.2023.101103_bb0600","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.16084","article-title":"Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane","volume":"187","author":"Andres","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101103_bb0605","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood-2008-03-146159","article-title":"Characterization of glycolytic enzyme interactions with murine erythrocyte membranes in wild-type and membrane protein knockout mice","volume":"112","author":"Campanella","year":"2008","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101103_bb0610","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0005-2744(73)90192-7","article-title":"On the molecular basis pyruvate kinase deficiency","volume":"321","author":"Van Berkel","year":"1973","journal-title":"Biochim Biophys Acta Enzymol"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2023.101103_bb0615","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.HS9.0000843984.82229.aa","article-title":"Evidence of noninferiority of mitapivat versus splenectomy in murine hereditary spherocytosis","volume":"6","author":"Matte","year":"2022","journal-title":"Hemasphere."},{"issue":"11","key":"10.1016\/j.blre.2023.101103_bb0620","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3324\/haematol.2016.142463","article-title":"New insights on hereditary erythrocyte membrane defects","volume":"101","author":"Andolfo","year":"2016","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.blre.2023.101103_bb0625","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2012-02-414037","article-title":"Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacity","volume":"121","author":"Rogers","year":"2013","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.blre.2023.101103_bb0630","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMra2212266","article-title":"Oxygen delivery in the treatment of anemia","volume":"387","author":"Bunn","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0635","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/bloodadvances.2020003028","article-title":"Piezo1-xerocytosis red cell metabolome shows impaired glycolysis and increased hemoglobin oxygen affinity","volume":"5","author":"Kiger","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0640","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2141.1972.tb03464.x","article-title":"Erythrocyte enzymatic abnormalities in HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified-serum test)","volume":"23","author":"Valentine","year":"1972","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0645","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood.V41.6.857.857","article-title":"Dyserythropoiesis, refractory anemia, and \u201cpreleukemia:\u201d metabolic features of the erythrocytes","volume":"41","author":"Valentine","year":"1973","journal-title":"Blood."},{"issue":"S45","key":"10.1016\/j.blre.2023.101103_bb0650","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-0609.1986.tb00844.x","article-title":"Red cell enzymes in myelodysplastic syndromes: a review","volume":"36","author":"Lintula","year":"2009","journal-title":"Scand J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101103_bb0655","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1620\/tjem.255.49","article-title":"Enzymatic changes in red blood cells of diamond-blackfan anemia","volume":"255","author":"Utsugisawa","year":"2021","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.blre.2023.101103_bb0660","series-title":"Agios at ASH 2022 IR Event. PYRUKYND Approval Webcast Presentation","first-page":"49","author":"Agios","year":"2022"},{"issue":"6","key":"10.1016\/j.blre.2023.101103_bb0665","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000207900","article-title":"Acquired pyruvate kinase deficiency with hemolysis in preleukemia","volume":"57","author":"Helmst\u00e4dter","year":"1977","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101103_bb0670","first-page":"1283","article-title":"Erythrocyte 2,3-diphosphoglycerate in liver diseases","volume":"82","author":"Nakano","year":"1987","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.blre.2023.101103_bb0675","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155260","article-title":"Regeneration of glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy","volume":"7","author":"Fu","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.blre.2023.101103_bb0680","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.15252\/embr.201643300","article-title":"PKM2, cancer metabolism, and the road ahead","volume":"17","author":"Dayton","year":"2016","journal-title":"EMBO Rep"},{"issue":"3390","key":"10.1016\/j.blre.2023.101103_bb0685","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/134627b0","article-title":"Chemistry of anaerobic recovery in muscle","volume":"134","author":"Parnas","year":"1934","journal-title":"Nature."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101103_bb0690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142232","article-title":"The pyruvate kinase activator mitapivat ameliorates anemia and prevents iron overload in a mouse model of hereditary spherocytosis","volume":"136","author":"Matt\u00e8","year":"2020","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.blre.2023.101160","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000}}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:34:21Z","timestamp":1724772861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":138,"alternative-id":["S0268960X23000644"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101103","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.blre.2023.101160","asserted-by":"object"}]},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101103"}}